These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 22212011

  • 1. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M, Karimi M.
    Transfus Med; 2012 Apr; 22(2):104-7. PubMed ID: 22212011
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
    Yarali N, Fişgin T, Duru F, Kara A, Ecin N, Fitoz S, Erden I.
    J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
    [Abstract] [Full Text] [Related]

  • 3. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Jan; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 4. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H, Garallahi F, Amini R.
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [Abstract] [Full Text] [Related]

  • 5. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
    Lee WS, Toh TH, Chai PF, Soo TL.
    J Paediatr Child Health; 2011 Aug; 47(8):535-40. PubMed ID: 21392144
    [Abstract] [Full Text] [Related]

  • 6. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Aug; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 7. Behavioral contracting to improve adherence in patients with thalassemia.
    Koch DA, Giardina PJ, Ryan M, MacQueen M, Hilgartner MW.
    J Pediatr Nurs; 1993 Apr; 8(2):106-11. PubMed ID: 8509968
    [Abstract] [Full Text] [Related]

  • 8. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.
    Modell B, Khan M, Darlison M.
    Lancet; 2000 Jun 10; 355(9220):2051-2. PubMed ID: 10885361
    [Abstract] [Full Text] [Related]

  • 9. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
    Nelson SC, Hennessy JM, McDonough EA, Guck KL.
    J Pediatr Hematol Oncol; 2006 Mar 10; 28(3):182-5. PubMed ID: 16679946
    [Abstract] [Full Text] [Related]

  • 10. A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.
    Elalfy MS, Massoud W, Elsherif NH, Labib JH, Elalfy OM, Elaasar S, von Mackensen S.
    Pediatr Blood Cancer; 2012 Jun 10; 58(6):910-5. PubMed ID: 22232075
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 12. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC, Ng DM, Fong DY, Ha SY, Lau YL.
    Am J Hematol; 2004 Aug 21; 76(4):398-404. PubMed ID: 15282678
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G.
    Haematologica; 1998 Sep 21; 83(9):788-90. PubMed ID: 9825575
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran.
    Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD.
    Thromb Haemost; 2006 Oct 21; 96(4):488-91. PubMed ID: 17003927
    [Abstract] [Full Text] [Related]

  • 15. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug 21; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C, Cohen A.
    J Pediatr; 1997 Jan 21; 130(1):86-8. PubMed ID: 9003855
    [Abstract] [Full Text] [Related]

  • 17. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M, Yano K, Fujisawa S.
    Rinsho Ketsueki; 1996 Apr 21; 37(4):303-10. PubMed ID: 8847800
    [Abstract] [Full Text] [Related]

  • 18. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug 21; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 19. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
    Cario H, Stahnke K, Kohne E.
    Klin Padiatr; 1999 Aug 21; 211(6):431-7. PubMed ID: 10592921
    [Abstract] [Full Text] [Related]

  • 20. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D, Prasad V, Anslow P, Lennox P.
    J Laryngol Otol; 2008 Nov 21; 122(11):1253-6. PubMed ID: 17931455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.